Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats

Drug Metabolism and Disposition

Volumn 39, Issue 10, 2011, Pages 1873-1882

  Yang, Jinfu ^a   Wang, Zhengping ^a   Fang, Ying ^a   Jiang, Jing ^a   Zhao, Frances ^a   Wong, Hansen ^a   Bennett, Mark K ^a   Molineaux, Christopher J ^a   Kirk, Christopher J ^a  

^a ONYX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARFILZOMIB; DRUG METABOLITE; ENZYME INHIBITOR; ONX 0912; PEPTIDASE; PR 047; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILE; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; EPOXIDE HYDROLYSIS; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; URINE;

ANIMALS; BILE; EPOXY COMPOUNDS; HYDROLYSIS; MALE; OLIGOPEPTIDES; PEPTIDE HYDROLASES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

RATTUS;

EID: 80053148350     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.039164     Document Type: Article

References (41)

1. Adams J (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4:349-360.
2. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, and Stein RL (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8:333-338. (Pubitemid 28072702)
3. Alsina M, Trudel S, Vallone M, Molineaux C, Kunkel L, and Goy A (2007) Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 110:411.
4. Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ, et al. (2011) Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 17:2734-2743.
5. Bennett MK and Kirk CJ (2008) Development of proteasome inhibitors in oncology and autoimmune diseases. Curr Opin Drug Discov Devel 11:616-625.
6. Borissenko L and Groll M (2007) 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev 107:687-717. (Pubitemid 46502369)
7. Bross PF, Kane R, Farrell AT, Abraham S, Benson K, Brower ME, Bradley S, Gobburu JV, Goheer A, Lee SL, et al. (2004) Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 10:3954-3964. (Pubitemid 38812468)
8. Chauhan D, Hideshima T, Mitsiades C, Richardson P, and Anderson KC (2005) Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 4:686-692. (Pubitemid 40601851)
9. Ciechanover A (2005) Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 6:79-87.
10. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
11. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, et al. (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67:6383-6391. (Pubitemid 47037522)
12. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, et al. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-675. (Pubitemid 46224166)
13. Groll M, Kim KB, Kairies N, Huber R, and Crews CM (2000) Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of alpha',beta'-epoxyketone proteasome inhibitors. J Am Chem Soc 122:1237-1238. (Pubitemid 30117471)
14. Hanada M, Sugawara K, Kaneta K, Toda S, Nishiyama Y, Tomita K, Yamamoto H, Konishi M, and Oki T (1992) Epoxomicin, a new antitumor agent of microbial origin. J Antibiot 45:1746-1752. (Pubitemid 23015454)
15. Hemeryck A, Geerts R, Monbaliu J, Hassler S, Verhaeghe T, Diels L, Verluyten W, Van Beijsterveldt L, Mamidi RN, Janssen C, et al. (2007) Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib. Cancer Chemother Pharmacol 60:777-787. (Pubitemid 47389383)
16. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
17. Jagannath S, Vij R, Kaufman JL, Martin T, Niesvizky R, Gabrail NY, Alsina M, Wong AF, Le MH, McCulloch L, et al. (2010) Long-term treatment and tolerability of the novel proteasome inhibitor carfilzomib (CFZ) in patients with relapsed and/or refractory multiple myeloma (R/R MM). Blood (ASH Annual Meeting Abstracts) 116:1953.
18. Jakubowiak AJ, Martin T, Singhal SB, Wang M, Vij R, Jagannath S, Lonial S, Kukreti V, Buadi F, Bray L, et al. (2010a) Responses and survival are not affected by cytogenetics in patients with relapsed and refractory multiple myeloma (R/R MM) treated with single-agent carfilzomib. Blood (ASH Annual Meeting Abstracts) 116:1942.
19. Jakubowiak AJ, Dytfeld D, Jagannath S, Vesole DH, Anderson TB, Nordgren BK, Lebovic D, Stockerl-Goldstein KE, Griffith KA, Hill MA, et al. (2010b) Carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma: initial results of phase I/II MMRC trial. Blood (ASH Annual Meeting Abstracts) 116:862.
20. Kim KB, Myung J, Sin N, and Crews CM (1999) Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency. Bioorg Med Chem Lett 9:3335-3340.
21. Kisselev AF and Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8:739-758. (Pubitemid 32752454)
22. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, Van Leeuwen FW, Chanan-Khan AA, et al. (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110:3281-3290. (Pubitemid 350106321)
23. Martin T, Singhal SB, Vij R, Wang M, Stewart AK, Jagannath S, Lonial S, Jakubowiak AJ, Kukreti V, Bahlis NJ, et al. (2010) Baseline peripheral neuropathy does not impact the efficacy and tolerability of the novel proteasome inhibitor carfilzomib (CFZ): results of a subset analysis of a phase 2 trial in patients with relapsed and refractory multiple myeloma (R/R MM). Blood (ASH Annual Meeting Abstracts) 116:3031.
24. Meng L, Kwok BH, Sin N, and Crews CM (1999a) Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res 59:2798-2801. (Pubitemid 29283111)
25. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, and Crews CM (1999b) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 96:10403-10408. (Pubitemid 29422570)
26. Mirabella AC, Pletnev AA, Downey SL, Florea BI, Shabaneh TB, Britton M, Verdoes M, Filippov DV, Overkleeft HS, and Kisselev AF (2011) Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. Chem Biol 18:608-618.
27. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, et al. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-684. (Pubitemid 46237441)
28. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, et al. (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427. (Pubitemid 35334752)
29. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, et al. (2007a) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25:3892-3901. (Pubitemid 47477266)
30. Orlowski RZ, Stewart K, Vallone M, Molineaux C, Kunkel L, Gericitano J, and O'Connor OA (2007b) Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematologic malignancies: phase 1 results. Blood (ASH Annual Meeting Abstracts) 110:409.
31. Papadopoulos K, Siegel DS, Singhal SB, Infante JR, Sausville EA, Gordon MS, Kauffman M, Woo T, Lee S, Bui L, et al. (2010) Phase 1b evaluation of the safety and efficacy of a 30-minute IV infusion of carfilzomib in patients with relapsed and/or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts) 116:3024.
32. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, et al. (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108-2121. (Pubitemid 41095144)
33. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617. (Pubitemid 36741588)
34. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, et al. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498. (Pubitemid 41007864)
35. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Jagannath S, Lonial S, Kukreti V, Bahlis NJ, Alsina M, et al. (2010) Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 116:985.
36. Singh J, Petter RC, Baillie TA, and Whitty A (2011) The resurgence of covalent drugs. Nat Rev Drug Discov 10:307-317.
37. Singhal SB, Siegel DS, Martin T, Vij R, Wang M, Jakubowiak AJ, Lonial S, Kukreti V, Zonder JA, Wong AF, et al. (2010) Pooled safety analysis from phase (Ph) 1 and 2 studies of carfilzomib (CFZ) in patients with relapsed and/or refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 116:1954.
38. Uttamsingh V, Lu C, Miwa G, and Gan LS (2005) Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos 33:1723-1728. (Pubitemid 41539972)
39. Venkatakrishnan K, Rader M, Ramanathan RK, Ramalingam S, Chen E, Riordan W, Trepicchio W, Cooper M, Karol M, Von Moltke L, et al. (2009) Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study. Clin Ther 31:2444-2458.
40. Vij R, Kaufman JL, Jakubowiak AJ, Stewart AK, Jagannath S, Kukreti V, McDonagh KT, Alsina M, Bahlis NJ, Belch A, et al. (2010) Carfilzomib: high single agent response rate with minimal neuropathy even in high-risk patients. Blood (ASH Annual Meeting Abstracts) 116:1938.
41. Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, Ho MN, Jiang J, Kirk CJ, Laidig GJ, et al. (2009) Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 52:3028-3038.